Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

Lyra Therapeutics (LYRA)

Lyra Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:LYRA
DateTimeSourceHeadlineSymbolCompany
10/01/202521:15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LYRALyra Therapeutics Inc
10/01/202521:15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LYRALyra Therapeutics Inc
10/01/202521:02Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LYRALyra Therapeutics Inc
13/12/202422:06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LYRALyra Therapeutics Inc
11/12/202423:54Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LYRALyra Therapeutics Inc
11/12/202423:39Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LYRALyra Therapeutics Inc
15/11/202400:48Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:LYRALyra Therapeutics Inc
14/11/202422:49Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:LYRALyra Therapeutics Inc
14/11/202422:48Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:LYRALyra Therapeutics Inc
14/11/202421:53Edgar (US Regulatory)Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:LYRALyra Therapeutics Inc
14/11/202417:00Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:LYRALyra Therapeutics Inc
12/11/202421:24Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:LYRALyra Therapeutics Inc
12/11/202421:18Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LYRALyra Therapeutics Inc
12/11/202421:01GlobeNewswire Inc.Lyra Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:LYRALyra Therapeutics Inc
18/10/202420:05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LYRALyra Therapeutics Inc
18/10/202420:05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LYRALyra Therapeutics Inc
15/10/202411:00GlobeNewswire Inc.Lyra Therapeutics Fully Enrolls Pivotal Phase 3 ENLIGHTEN 2 Trial of LYR-210 for the Treatment of Chronic RhinosinusitisNASDAQ:LYRALyra Therapeutics Inc
27/09/202411:00GlobeNewswire Inc.Lyra Therapeutics to Present Study Results for LYR-210 and LYR-220 in Two Presentations at the ARS and AAO-HNS Annual MeetingsNASDAQ:LYRALyra Therapeutics Inc
14/08/202420:16Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:LYRALyra Therapeutics Inc
14/08/202420:09Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LYRALyra Therapeutics Inc
14/08/202420:01GlobeNewswire Inc.Lyra Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:LYRALyra Therapeutics Inc
23/07/202420:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LYRALyra Therapeutics Inc
18/06/202420:06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LYRALyra Therapeutics Inc
14/06/202420:10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LYRALyra Therapeutics Inc
14/06/202420:10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LYRALyra Therapeutics Inc
14/06/202420:10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LYRALyra Therapeutics Inc
07/06/202420:15Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:LYRALyra Therapeutics Inc
21/05/202413:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LYRALyra Therapeutics Inc
21/05/202413:14GlobeNewswire Inc.Lyra Therapeutics Announces Cost-Cutting Measures to Preserve CapitalNASDAQ:LYRALyra Therapeutics Inc
06/05/202411:59GlobeNewswire Inc.Lyra Therapeutics Reports Topline Results from Phase 3 ENLIGHTEN 1 Trial for LYR-210 in Chronic RhinosinusitisNASDAQ:LYRALyra Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:LYRA